Fralex Therapeutics Inc. (TSX: FXI). Fralex is a medical technology company focused on developing and commercializing Complex Neural Pulse or CNP, a novel neuromodulation therapy for chronic pain, which utilizes specifically designed, low-frequency electromagnetic pulses. Fralex has received approval from the FDA to proceed with its pivotal clinical trial (the "RELIEF trial") to evaluate the safety and effectiveness of CNP in the treatment of chronic pain associated with fibromyalgia. The trial is to be conducted at leading medical centres within the US and Canada. Fralex Therapeutics Inc. recently completed its initial public offering and commenced trading on the TSX on February 13, 2007.